Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NCF1 | P14598 | 1/20 | 0.38 |
| ▸ | DUT | P33316 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4652904 | 0.83 | BACE1 (0.36) | CYP3A4DUTTSHRNTSR1DGAT1 | |
| SCHEMBL13302934 | 0.83 | DUT (0.34) | DUTDGAT1 | |
| SCHEMBL7717528 | 0.83 | DUT (0.37) | DUTTAAR1DGAT1 | |
| SCHEMBL4465723 | 0.83 | ALDH1A1 (0.43) | CYP3A4NCF1DUTTSHRDGAT1 | |
| SCHEMBL4654972 | 0.83 | NOX1 (0.45) | CYP2C19SMN1; SMN2EGFR | |
| SCHEMBL6933156 | 0.82 | DUT (0.33) | DUTDGAT1 | |
| SCHEMBL3019402 | 0.82 | MTNR1A (0.34) | KMT2ADUTTSHRTAAR1EGFR | |
| SCHEMBL98656 | 0.80 | ALDH1A1 (0.34) | DUT | |
| SCHEMBL1234774 | 0.80 | ALDH1A1 (0.49) | MEN1KMT2ASMN1; SMN2DUTDGAT1 | |
| SCHEMBL13302932 | 0.80 | DUT (0.32) | DUTDGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8197722-B2 | Irradiating the compound (containing two electron donor groups and a bridge of pi-conjugated bonds containing electron donor groups) with light, and the compound is converted to a multi-photon electronically excited state | THE CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2012-06-12 | — | — | US | disclosed |
| US-8197722-B2 | Irradiating the compound (containing two electron donor groups and a bridge of pi-conjugated bonds containing electron donor groups) with light, and the compound is converted to a multi-photon electronically excited state | THE CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2012-06-12 | — | — | US | disclosed |
| US-20100152338-A1 | NONLINEAR OPTICAL MATERIAL COMPOSITION AND METHOD OF MANUFACTURE | NITTO DENKO CORPORATION (JP) | 2010-06-17 | — | — | US | disclosed |
| US-20100152338-A1 | NONLINEAR OPTICAL MATERIAL COMPOSITION AND METHOD OF MANUFACTURE | NITTO DENKO CORPORATION (JP) | 2010-06-17 | — | — | US | disclosed |
| WO-2008109701-A1 | NONLINEAR OPTICAL MATERIAL COMPOSITION AND METHOD OF MANUFACTURE | NITTO DENKO CORPORATION (JP) | 2008-09-12 | — | — | WO | disclosed |
| EP-0747704-B1 | Immunoassay element containing a diaryl telluride compound to increase its stability | ORTHO CLINICAL DIAGNOSTICS INC (US) | 2003-12-10 | — | — | EP | disclosed |
| EP-0903583-B1 | Reduction in first slide bias and improved enzyme stability by incorporation of diaryl tellurides in the gravure layer of dry-film immunoassay elements | ORTHO CLINICAL DIAGNOSTICS INC (US) | 2003-11-12 | — | — | EP | disclosed |
| US-20020185634-A1 | Two-photon or higher-order absorbing optical materials and methods of use | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2002-12-12 | — | — | US | disclosed |
| US-6267913-B1 | IN HOLOGRAPHYL, BIOLOGY, OPTICAL DATA STORAGE | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2001-07-31 | — | — | US | disclosed |
| WO-1998021521-A9 | TWO-PHOTON OR HIGHER-ORDER ABSORBING OPTICAL MATERIALS AND METHODS OF USE | CALIFORNIA INST OF TECHN (US) | 2000-03-02 | — | — | WO | disclosed |
| EP-0903583-A2 | Reduction in first slide bias and improved enzyme stability by incorporation of diaryl tellurides in the gravure layer of dry-film immunoassay elements | Ortho-Clinical Diagnostics, Inc. (US) | 1999-03-24 | — | — | EP | disclosed |
| WO-1998021521-A1 | TWO-PHOTON OR HIGHER-ORDER ABSORBING OPTICAL MATERIALS AND METHODS OF USE | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1998-05-22 | — | — | WO | disclosed |
| EP-0747704-A2 | Immunoassay element containing a diaryl telluride compound to increase its stability | Johnson & Johnson Clinical Diagnostics, Inc. (US) | 1996-12-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152338-A1 | NONLINEAR OPTICAL MATERIAL COMPOSITION AND METHOD OF MANUFACTURE | C5, OR10J3, C1S | MEN1 4278/4885CYP3A4 1649/4885CYP2C9 1996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.